News on research and diagnostics for metabolic disorders and metabolic diseases.
The expanded clearance includes use of the test to assess a patient's risk of developing diabetes. The assay was cleared to run on the Afinion AS100 Analyzer.
The study found that for some patients the standard practice of performing a second confirmatory blood test is not necessary, which could streamline care.
Patia will offer the assay, which uses mass spectrometry to measure proteins to predict risk of diabetic kidney disease, as a laboratory-developed test.